Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Various enteric microorganisms” represents the complex ecosystem of microorganisms inhabiting the gastrointestinal tract. The four dominant bacterial phyla are Firmicutes (Bacillota), Bacteroidetes (Bacteroidota), Actinobacteria (Actinomycetota), and Proteobacteria (Pseudomonadota)[1][4]. Major genera include Bacteroides (constituting about 30% of gut bacteria[4]), Clostridium, Faecalibacterium, Eubacterium, Ruminococcus, Bifidobacterium, Escherichia, and Lactobacillus[1][4]. The family Enterobacteriaceae specifically includes over 30 genera and more than 100 species of Gram-negative bacteria[2], containing both harmless symbionts and pathogens like Salmonella, E. coli, Klebsiella, and Shigella[2]. The microbiota composition varies across different regions of the digestive tract and between individuals, remaining relatively stable within an individual over time but influenced by age, diet, lifestyle, and medication use[1][4].
Not applicable as a therapeutic target, though the microbiota can be modulated through probiotics, prebiotics, antibiotics, or fecal microbiota transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Various enteric microorganisms.